Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. decreased its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) by 51.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 22,146 shares of the company’s stock after selling 23,374 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Ikena Oncology were worth $38,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Blue Owl Capital Holdings LP boosted its stake in Ikena Oncology by 5.1% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 4,091,118 shares of the company’s stock worth $6,750,000 after buying an additional 200,000 shares during the last quarter. BML Capital Management LLC lifted its holdings in shares of Ikena Oncology by 23.6% during the 3rd quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock worth $1,251,000 after acquiring an additional 138,174 shares during the period. NEA Management Company LLC boosted its position in shares of Ikena Oncology by 5.3% in the third quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock worth $1,038,000 after acquiring an additional 30,013 shares during the last quarter. Sofinnova Investments Inc. grew its holdings in Ikena Oncology by 230.7% in the second quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock valued at $631,000 after purchasing an additional 266,904 shares during the period. Finally, Acadian Asset Management LLC increased its position in Ikena Oncology by 15.2% during the second quarter. Acadian Asset Management LLC now owns 325,713 shares of the company’s stock worth $536,000 after purchasing an additional 42,931 shares during the last quarter. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Ikena Oncology Price Performance

Shares of IKNA stock opened at $1.68 on Friday. Ikena Oncology, Inc. has a fifty-two week low of $1.22 and a fifty-two week high of $2.32. The firm’s 50 day moving average price is $1.71 and its two-hundred day moving average price is $1.69. The stock has a market cap of $81.08 million, a price-to-earnings ratio of -1.37 and a beta of 0.49.

Ikena Oncology (NASDAQ:IKNA) last posted its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.08. On average, equities analysts forecast that Ikena Oncology, Inc. will post -0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on IKNA shares. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Ikena Oncology in a research note on Monday, November 11th. Wedbush reissued a “neutral” rating and set a $2.00 price target on shares of Ikena Oncology in a research report on Thursday, November 7th.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.